실적분석 2026년 7월 29일

Glaukos ($GKOS) Q2 2026 Earnings Analysis — Revenue and Adjusted Earnings Both Beat, Full-Year Guidance Raised Sharply

Earnings Scorecard

Revenue: $186 million (+50% year-over-year, estimate $151 million) ✅ Beat

EPS: Adjusted -$0.14 (estimate -$0.22) ✅ Beat

Guidance: Raised — 2026 revenue $680–$700 million (prior $620–$635 million)

Stock Reaction: After-hours +8.38% ($175.21) — as of 07:30 KST 06:17

Positives

Revenue Surge: $186 million beat the $151 million estimate by a wide margin, +50% year-over-year

U.S. Glaucoma: $118.5 million, +64% year-over-year, a new record

Full-Year Guidance Raised: 2026 revenue outlook lifted significantly to $680–$700 million

Glaukos ($GKOS) is an ophthalmic pharmaceutical and medical device company focused on treatments for glaucoma, corneal, and retinal diseases. Q2 net revenue came in at $185.6 million, up 50% from $124.1 million a year earlier (+49% on a constant-currency basis), comfortably ahead of the $151 million the market had expected. Glaucoma segment revenue was $155.2 million (+50%), with U.S. glaucoma alone surging 64% to $118.5 million and leading the growth.

Adjusted (non-GAAP) gross margin was roughly 85%, while GAAP gross margin was approximately 82%—both improving year-over-year. Adjusted EPS was -$0.14, a narrower loss than the -$0.22 analysts had forecast. Management said the growth momentum from iDose TR and Epioxa is continuing and, accordingly, raised its full-year revenue outlook substantially. Cash and equivalents at quarter-end stood at about $289.3 million, with no debt.

Shortcomings

Still in the Red: Adjusted EPS of -$0.14 and a net loss of $8.3 million persist

Cost Surge: SG&A +39% and R&D +40%, keeping the loss-making structure in place

Concentrated Growth Risk: Growth is heavily dependent on iDose and Epioxa commercialization results

Revenue is expanding quickly, but profitability has yet to arrive. On a GAAP basis, the net loss was $18.4 million (-$0.31 per share), and on an adjusted basis the loss was $8.3 million (-$0.14 per share). The adjusted figure included about $1.5 million of in-process R&D charges tied to an acquisition, adding roughly two cents per share of additional pressure.

SG&A rose 39% to $116.1 million, and R&D climbed 40% to $51.3 million. New product launches and pipeline investment are supporting growth but also driving the cost increases. If the pace of adoption for iDose TR and Epioxa—two products management continues to emphasize—slows, or if reimbursement, supply, or regulatory issues emerge, the current high-growth narrative could wobble. The company itself has flagged the successful commercialization of these therapies as one of its key risk factors.

What the Company Said

CEO Thomas Burns explained that the record Q2 results reflect execution against the company's global commercial and development priorities, and that Glaukos is well-positioned to sustain momentum around the two growth pillars of iDose TR and Epioxa. The tone was clearly focused on continuing to develop drop-free platform technology and raise the standard of care for chronic eye diseases.

The significant upward revision to the full-year revenue outlook fits that same message. More important than the raw numbers is the company's confidence that this is structural, new-product-led growth rather than a short-term bounce. The market appears to have read this as stronger growth visibility alongside the earnings surprise. However, the company did not provide quarterly EPS guidance; the outlook centers on a revenue range that reflects the latest currency assumptions.

Market Reaction and Points to Watch

The market appears to have priced in all three drivers at once: revenue coming in well above estimates, a narrower adjusted loss, and a sizable upward revision to full-year revenue guidance. This is a familiar pattern in growth medical-device and ophthalmology themes, where confidence about "how much faster can these products sell from here" drives the stock more than any single quarter's print. The after-hours strength on the scorecard is most naturally read as the result of all three forces aligning.

Watch how much U.S. and international revenue contribution from iDose TR and Epioxa expands each quarter.

Watch whether SG&A and R&D growth decelerate relative to revenue growth, allowing the loss to narrow further.

Monitor the feasibility of hitting the high end of the full-year revenue range and whether guidance is revised up or down in the second half.